清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Undetectable-Minimal Residual Disease (U-MRD6) (10-6 sensitivity) Is Associated with Best Progression-Free Survival for Patients Who Achieve Bone Marrow Undetectable MRD4 (10-4 sensitivity) with First-Line FCR

微小残留病 IGHV@ 骨髓 外周血单个核细胞 内科学 医学 肿瘤科 多路复用 免疫学 慢性淋巴细胞白血病 生物 白血病 生物信息学 遗传学 体外
作者
Philip A. Thompson,Jaya Srivastava,Paolo Strati,Jeffrey L. Jorgensen,Joyce Breaker,Tyler Hether,Michael J. Keating,Susan O’Brien,Alessandra Ferrajoli,Jan A. Burger,Zeev Estrov,Nitin Jain,William G. Wierda
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 3137-3137 被引量:1
标识
DOI:10.1182/blood-2018-99-117864
摘要

Abstract Introduction Patients (pts) with CLL who achieve blood or bone marrow (BM) undetectable minimal residual disease (U-MRD), assessed with a sensitivity of at least 10-4 (MRD4), have long PFS after 1st-line treatment with FCR. A proportion of pts with mutated immunoglobulin heavy chain variable gene (M-IGHV) may be cured of CLL, given the reported PFS beyond 10 yrs. In contrast, most pts with unmutated (UM)-IGHV relapse, despite achieving BM U-MRD4. The likelihood of relapse and relapse kinetics relate to CLL biology, including depth of remission and proliferation rate. MRD testing using next generation sequencing (NGS) can achieve sensitivity up to 10-6 (MRD6) and can also be used to test for circulating tumor DNA in plasma, which may reflect residual tumor in the tissue (eg. lymph nodes), not detectable in the cellular fraction of blood or BM. To better assess the depth of remission following first-line FCR treatment for CLL, we performed NGS MRD6 testing in BM, peripheral blood mononuclear cells (PBMC) and plasma of pts enrolled in a single center, prospective, phase II study. All pts had BM U-MRD4 by 4-color flow cytometry (FLC) at the end of treatment (EOT). Methods The following EOT samples from 62 pts were analyzed for MRD6: 57 BM, 29 PBMC and 32 plasma. Adaptive Biotechnologies' NGS MRD assay uses multiplex PCR and NGS to amplify rearrangements within the B cell receptor CDR3 and identify disease associated clonotypes. Specifically, the assay utilizes multiplexed primers complementing V-J rearrangements (IGH, IGK/L) and D-J (IGH) rearrangements. Pre-treatment samples were sequenced to determine the malignant clonotype, which was then quantitated in the EOT samples, within the polyclonal background. Results Regardless of assay sensitivity, U-MRD rates by HTS according to sample type were: 14/57 (25%) in BM; 16/29 (55%) in PBMC; 24/32 (75.0%) in plasma. All pts with MRD+ in plasma simultaneously had detectable disease in either BM or PBMC. Of 16 pts who had U-MRD in PBMC, 7/12 with simultaneous BM samples were MRD+ in BM. In all patients, there was a trend toward increased likelihood of U-MRD in pts with M-IGHV [12/30 (40%) vs 4/24 (17%), OR 3.3 (0.9-12.2), p = 0.06]. Assay sensitivity varies according to amount of DNA in the sample and with malignant clonotype. Sensitivity of at least 10-6 was achieved in 74% and 62% of samples in BM and PBMC, respectively. Among patients with U-MRD by NGS: 4/14 BM (1.06-3.2 x 10-6, median 1.96 x 10-6) and 8/16 PBMC (1.001 x 10-6 to 3.56 x 10-6, median 1.54 x 10-6) samples did not have sensitivity of 10-6. Notably, 3 pts also had detectable disease at a level <10-6 in BM, 2 of whom relapsed (Figure C). Median follow-up was 82 months (mo) (range: 28-112.4). Fifty-six of 62 (90.3%) pts are alive; 28 are progression-free. Median PFS for the whole cohort was 89 mo. When PFS was analyzed according to whether MRD was detected or not (regardless of sensitivity), pts with U-MRD at the EOT had superior PFS vs pts with MRD+, whether the sample type used was BM (p=0.02, median NR vs 67 mo) or PBMC (p=0.02, median NR vs 74 mo), Figure A, B. When analyzed according to whether MRD was <10-6vs >/=10-6 (MRD6), 40/53 (75%) in BM and 13/21 (62%) in PBMC were MRD6+. For this analysis, pts were excluded if they had U-MRD but assay sensitivity did not reach at least 10-6. Despite smaller n, there were trends toward shorter PFS for pts with MRD6+ vs U-MRD6 (Figure C, D). Discussion The majority of pts with BM U-MRD4 after first-line FCR were MRD6+ and these patients had shorter PFS; MRD analysis with a more sensitive assay may therefore more accurately assign prognosis. Not accounting for sensitivity, a higher proportion of BM than PBMC samples were MRD+. Plasma analysis was uninformative as all pts MRD+ in plasma were MRD+ in simultaneous BM or PBMC samples. Defining prognostically-relevant thresholds for MRD using more sensitive methodology is important, particularly if U-MRD is used a surrogate for PFS in clinical trials or as an endpoint for treatment cessation. MRD6 may become increasingly relevant if venetoclax-based regimens and the addition of novel agents to chemoimmunotherapy achieve U-MRD6 in more patients than FCR. In this retrospective study, a number of samples did not achieve 10-6 sensitivity; optimization of sample collection is important to achieve 10-6 sensitivity in most pts. Finally, additional studies will be required to determine the risk for and kinetics of relapse in patients with low-level MRD6+. Disclosures Thompson: AbbVie: Honoraria, Research Funding; Gilead Sciences: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Research Funding; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees. Srivastava:Adaptive Biotechnologies: Employment. Hether:Adaptive Biotechnologies: Employment. O'Brien:Acerta: Research Funding; Sunesis: Consultancy, Research Funding; Regeneron: Research Funding; GlaxoSmithKline: Consultancy; Celgene: Consultancy; Amgen: Consultancy; Pharmacyclics: Consultancy, Research Funding; Vaniam Group LLC: Consultancy; Abbvie: Consultancy; Aptose Biosciences Inc.: Consultancy; Pfizer: Consultancy, Research Funding; TG Therapeutics: Consultancy, Research Funding; Janssen: Consultancy; Astellas: Consultancy; Alexion: Consultancy; Kite Pharma: Research Funding; Gilead: Consultancy, Research Funding. Jain:ADC Therapeutics: Research Funding; Celgene: Research Funding; Abbvie: Research Funding; Seattle Genetics: Research Funding; Pharmacyclics: Research Funding; Incyte: Research Funding; Genentech: Research Funding; Infinity: Research Funding; Astra Zeneca: Research Funding; BMS: Research Funding; Pfizer: Research Funding; Servier: Research Funding; ADC Therapeutics: Research Funding; Verastem: Research Funding; Seattle Genetics: Research Funding; Cellectis: Research Funding; Incyte: Research Funding; Celgene: Research Funding; Adaptive Biotechnologioes: Research Funding; Astra Zeneca: Research Funding; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Research Funding; Verastem: Research Funding; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Cellectis: Research Funding; Astra Zeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologioes: Research Funding; Verastem: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Verastem: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novimmune: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novimmune: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Wierda:Genentech: Research Funding; AbbVie, Inc: Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
甜蜜的夕阳完成签到,获得积分10
刚刚
清爽的天川完成签到,获得积分10
13秒前
灵巧怀曼完成签到,获得积分10
22秒前
yan完成签到,获得积分10
30秒前
美满尔蓝完成签到,获得积分10
31秒前
dianeil发布了新的文献求助10
34秒前
舒适的妍完成签到,获得积分10
34秒前
丰富广缘完成签到,获得积分10
37秒前
求求了给篇文献完成签到,获得积分10
41秒前
温暖友易完成签到,获得积分10
41秒前
2s完成签到,获得积分10
43秒前
43秒前
腼腆的冰安完成签到,获得积分10
45秒前
顺利毛豆完成签到,获得积分10
46秒前
陈微完成签到,获得积分10
46秒前
2s发布了新的文献求助10
48秒前
能毕业就行完成签到,获得积分10
49秒前
单薄飞双完成签到,获得积分10
51秒前
苏苏完成签到,获得积分10
51秒前
张永和完成签到,获得积分10
53秒前
威武的成协完成签到,获得积分10
54秒前
无情捕完成签到,获得积分10
55秒前
科研绿老头完成签到,获得积分10
1分钟前
小蘑菇的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
深情安青的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
周新哲完成签到,获得积分10
1分钟前
Muth完成签到,获得积分10
1分钟前
dingyushu完成签到,获得积分10
1分钟前
ZF完成签到,获得积分10
1分钟前
WULAVIVA完成签到,获得积分10
1分钟前
2dingyushu完成签到,获得积分10
1分钟前
仇敌克星完成签到,获得积分10
1分钟前
baa完成签到,获得积分10
1分钟前
du完成签到,获得积分10
1分钟前
zheng完成签到,获得积分10
1分钟前
Beto发布了新的文献求助10
1分钟前
慢波完成签到,获得积分10
1分钟前
9dingyushu完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185411
求助须知:如何正确求助?哪些是违规求助? 9574140
关于积分的说明 21834410
捐赠科研通 7782895
什么是DOI,文献DOI怎么找? 3434567
关于科研通互助平台的介绍 2558844
邀请新用户注册赠送积分活动 2481280